Comparing COL7A1 gene expression in fibroblast cells of dystrophic epidermolysis bullosa patients with clinical responses to autologous fibroblasts transplantation
Keywords:RDEB, COL7A1, Gene expression, Fibroblast, Transplantation, clinical trial, dermal-epidermal junction
Objectives: This clinical research aimed to establish autologous fibroblasts transplantation as a possible treatment for patients with DEJ. The COL7A1 gene expression was also evaluated.
Methods: Six patients (3M and 3F), 4 with no recurrent wounds and 2 with recurrent wounds after surgery, and 15 healthy subjects were included in the study as controls. Quantitative real-time polymerase chain reaction (real-time PCR) analysis of the COL7A1 gene was performed using an oligonucleotide primer pair designed to amplify across the exon/exon junction.
Results: The COL7A1 expression level was down-regulated at exons 26-27, 47-48, 96-97, and 116-117 in all patients′ fibroblasts compared with the healthy controls. However, the expression of the COL7A1 gene in the fibroblasts of the patients with a positive response to the treatment was not significantly changed compared with the patients with the poor response. (ClinicalTrials.gov NCT01908088)
Conclusion: In this study the mRNA expression levels of COL7A1 were significantly less in the patients when compared with healthy controls. However the COL7A1 expression after autologous fibroblasts transplantation was not different between the two groups of patients, and further examination is needed to elucidate the mechanism of the treatment.
Baardman R, Yenamandra V, Duipmans J, Pasmooij A, Jonkman M, van den Akker P, et al. Novel insights into the epidemiology of epidermolysis bullosa (EB) from the Dutch EB Registry: EB more common than previously assumed? Journal of the European Academy of Dermatology and Venereology. 2021;35(4):995-1006.
Eichstadt S, Tang JY, Solis DC, Siprashvili Z, Marinkovich MP, Whitehead N, et al. From Clinical Phenotype to Genotypic Modelling: Incidence and Prevalence of Recessive Dystrophic Epidermolysis Bullosa (RDEB). Clinical, cosmetic and investigational dermatology. 2019;12:933.
Yadav RS, Jayswal A, Shrestha S, Gupta SK, Paudel U. Dystrophic Epidermolysis Bullosa. JNMA; journal of the Nepal Medical Association. 2018;56(213):879-82.
Zeng M, Alshehri F, Zhou D, Lara-Sáez I, Wang X, Li X, et al. Efficient and Robust Highly Branched Poly (β-amino ester)/Minicircle COL7A1 Polymeric Nanoparticles for Gene Delivery to Recessive Dystrophic Epidermolysis Bullosa Keratinocytes. ACS applied materials & interfaces. 2019;11(34):30661-72.
Lwin SM, Syed F, Di W-L, Kadiyirire T, Liu L, Guy A, et al. Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa. JCI insight. 2019;4(11).
Mansbridge JN, Liu K, Pinney RE, Patch R, Ratcliffe A, Naughton GK. Growth factors secreted by fibroblasts: role in healing diabetic foot ulcers. Diabetes, Obesity and Metabolism. 1999;1(5):265-79.
Takehara K. Growth regulation of skin fibroblasts. Journal of dermatological science. 2000;24:S70-S7.
Park H-H, Park N-Y, Kim S-G, Jeong K-T, Lee E-J, Lee E. Potential wound healing activities of galla rhois in human fibroblasts and keratinocytes. The American journal of Chinese medicine. 2015;43(08):1625-36.
Oever MV, Twaroski K, Osborn MJ, Wagner JE, Tolar J. Inside out: regenerative medicine for recessive dystrophic epidermolysis bullosa. Pediatric research. 2018;83(1):318-24.
Christofolini DM, Ceroni JRM, Soares GG, Lamy GB, Calvo ACN, Santos TAd, et al. Reproductive alternatives for patients with dystrophic epidermolysis bullosa. Einstein (São Paulo). 2019;17(3).
Fine J-D, Bruckner-Tuderman L, Eady RA, Bauer EA, Bauer JW, Has C, et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. Journal of the American Academy of Dermatology. 2014;70(6):1103-26.
Kim M, Li M, Intong-Wheeler LR, Tran K, Marucci D, Murrell DF. Epidemiology and outcome of squamous cell carcinoma in epidermolysis bullosa in Australia and New Zealand. Acta dermato-venereologica. 2018;98(1-2):70-6.
Siprashvili Z, Nguyen NT, Gorell ES, Loutit K, Khuu P, Furukawa LK, et al. Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa. JAMA. 2016;316(17):1808-17.
Zhou X, Zhang Y, Zhao M, Jian Y, Huang J, Luo X, et al. Surgical management of hand deformities in patients with recessive dystrophic epidermolysis bullosa. Journal of Plastic Surgery and Hand Surgery. 2020;54(1):33-9.
Latella MC, Cocchiarella F, De Rosa L, Turchiano G, Gonçalves MA, Larcher F, et al. Correction of recessive dystrophic epidermolysis bullosa by transposon-mediated integration of COL7A1 in transplantable patient-derived primary keratinocytes. Journal of Investigative Dermatology. 2017;137(4):836-44.
Rashidghamat E, McGrath JA. Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa. Intractable & rare diseases research. 2017;6(1):6-20.
Twaroski K, Eide C, Riddle M, Xia L, Lees C, Chen W, et al. Revertant mosaic fibroblasts in recessive dystrophic epidermolysis bullosa. British Journal of Dermatology. 2019;181(6):1247-53.
Tuncer S, Sezgin B, Kaya B, Ayhan S, Latifoglu O. An algorithmic approach for the management of hand deformities in dystrophic epidermolysis bullosa. Journal of plastic surgery and hand surgery. 2018;52(2):80-6.
Eisenberg M, Llewelyn D. Surgical management of hands in children with recessive dystrophic epidermolysis bullosa: use of allogeneic composite cultured skin grafts. British journal of plastic surgery. 1998;51(8):608-13.
Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic acids research. 2001;29(9):e45.
Cianfarani F, Zambruno G, Castiglia D, Odorisio T. Pathomechanisms of altered wound healing in recessive dystrophic epidermolysis bullosa. The American journal of pathology. 2017;187(7):1445-53.
Yan Y, Meng Z, Hao S, Wang F, Jin X, Sun D, et al. Five novel COL7A1 gene mutations in three Chinese patients with recessive dystrophic epidermolysis bullosa. Annals of Clinical & Laboratory Science. 2018;48(1):100-5.
Saeidian A, Youssefian L, Moreno Trevino M, Fortuna G, Vahidnezhad H, Atanasova V, et al. Seven novel COL 7A1 mutations identified in patients with recessive dystrophic epidermolysis bullosa from Mexico. Clinical and experimental dermatology. 2018;43(5):579-84.
Bornert O, Kühl T, Bremer J, Van Den Akker PC, Pasmooij AM, Nyström A. Analysis of the functional consequences of targeted exon deletion in COL7A1 reveals prospects for dystrophic epidermolysis bullosa therapy. Molecular Therapy. 2016;24(7):1302-11.
Marinkovich MP, Tang JY. Gene therapy for epidermolysis bullosa. Journal of Investigative Dermatology. 2019;139(6):1221-6.
Jacków J, Titeux M, Portier S, Charbonnier S, Ganier C, Gaucher S, et al. Gene-corrected fibroblast therapy for recessive dystrophic epidermolysis bullosa using a self-inactivating COL7A1 retroviral vector. Journal of Investigative Dermatology. 2016;136(7):1346-54.
Woodley DT, Chen M. Recessive Dystrophic Epidermolysis Bullosa: Advances in the Laboratory Leading to New Therapies. The Journal of investigative dermatology. 2015;135(7):1705-7.
Murauer EM, Gache Y, Gratz IK, Klausegger A, Muss W, Gruber C, et al. Functional correction of type VII collagen expression in dystrophic epidermolysis bullosa. Journal of Investigative Dermatology. 2011;131(1):74-83.
Vahidnezhad H, Youssefian L, Zeinali S, Saeidian AH, Sotoudeh S, Mozafari N, et al. Dystrophic Epidermolysis Bullosa: COL7A1 Mutation Landscape in a Multi-Ethnic Cohort of 152 Extended Families with High Degree of Customary Consanguineous Marriages. The Journal of investigative dermatology. 2017;137(3):660-9.
Wong T, Gammon L, Liu L, Mellerio JE, Dopping-Hepenstal PJ, Pacy J, et al. Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. Journal of Investigative Dermatology. 2008;128(9):2179-89.
Takashima S, Shinkuma S, Fujita Y, Nomura T, Ujiie H, Natsuga K, et al. Efficient gene reframing therapy for recessive dystrophic epidermolysis bullosa with CRISPR/Cas9. Journal of Investigative Dermatology. 2019;139(8):1711-21. e4.
Jacków J, Titeux M, Portier S, Charbonnier S, Ganier C, Gaucher S, Hovnanian A. Gene-
corrected fibroblast therapy for recessive dystrophic epidermolysis bullosa using a self-inactivating COL7A1 retroviral vector. Journal of Investigative Dermatology. 2016 Jul 1;136(7):1346-54.
Takashima S, Shinkuma S, Fujita Y, Nomura T, Ujiie H, Natsuga K, Iwata H, Nakamura H, Vorobyev A, Abe R, Shimizu H. Efficient gene reframing therapy for recessive dystrophic epidermolysis bullosa with CRISPR/Cas9. Journal of Investigative Dermatology. 2019 Aug 1;139(8):1711-21.
Matsumura W, Fujita Y, Shinkuma S, Suzuki S, Yokoshiki S, Goto H, Hayashi H, Ono K, Inoie M, Takashima S, Nakayama C. Cultured Epidermal Autografts from Clinically Revertant Skin as a Potential Wound Treatment for Recessive Dystrophic Epidermolysis Bullosa. Journal of Investigative Dermatology. 2019 Oct 1;139(10):2115-24.
How to Cite
Copyright (c) 2023 Journal of Contemporary Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.